13D Filing: SC Fundamental Value Fund, L.P. and Aviragen Therapeutics Inc. (AVIR)

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
DC 20549

SCHEDULE
13D/A

(Amendment
No. 2)

(Rule
13d-101)

information
to be included in statements filed pursuant
to rules 13d-1(a) and amendments thereto
filed
pursuant to rule 13d-2(a)1

aviragen Therapeutics, Inc.

(Name of Issuer) Common Stock, par value $0.10 per share

(Title of Class of Securities) 053761102

(CUSIP Number) Neil H. Koffler c/o SC Fundamental LLC 747 Third Avenue, 27th Floor New York, New York 10017

(Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications) January 16, 2018

(Date
of Event Which Requires Filing of this Statement)

                If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. o

 

Note: Schedules
filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be sent.

 

1            The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

 

The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).